Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 6
2005 6
2006 13
2007 7
2008 7
2009 3
2010 4
2011 9
2012 8
2013 14
2014 6
2015 2
2016 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
Arteaga CL, Engelman JA. Arteaga CL, et al. Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025. Cancer Cell. 2014. PMID: 24651011 Free PMC article. Review.
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Balko JM, et al. Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19. Cancer Discov. 2014. PMID: 24356096 Free PMC article.
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. Wang SE, et al. Cancer Cell. 2006 Jul;10(1):25-38. doi: 10.1016/j.ccr.2006.05.023. Cancer Cell. 2006. PMID: 16843263 Free article.
Does lapatinib work against HER2-negative breast cancers?
Mayer IA, Arteaga CL. Mayer IA, et al. Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179241 Free PMC article. Review.
New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.
Abramson V, Arteaga CL. Abramson V, et al. Clin Cancer Res. 2011 Mar 1;17(5):952-8. doi: 10.1158/1078-0432.CCR-09-1947. Epub 2011 Jan 19. Clin Cancer Res. 2011. PMID: 21248299 Free PMC article. Review.
Targeting the TGF beta signaling network in human neoplasia.
Dumont N, Arteaga CL. Dumont N, et al. Cancer Cell. 2003 Jun;3(6):531-6. doi: 10.1016/s1535-6108(03)00135-1. Cancer Cell. 2003. PMID: 12842082 Free article. Review. No abstract available.
Inhibition of TGFbeta signaling in cancer therapy.
Arteaga CL. Arteaga CL. Curr Opin Genet Dev. 2006 Feb;16(1):30-7. doi: 10.1016/j.gde.2005.12.009. Epub 2005 Dec 27. Curr Opin Genet Dev. 2006. PMID: 16377175 Review.
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.
Garrett JT, Arteaga CL. Garrett JT, et al. Cancer Biol Ther. 2011 May 1;11(9):793-800. doi: 10.4161/cbt.11.9.15045. Epub 2011 May 1. Cancer Biol Ther. 2011. PMID: 21307659 Free PMC article. Review.
Inhibiting tyrosine kinases: successes and limitations.
Arteaga CL. Arteaga CL. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S79-83. Cancer Biol Ther. 2003. PMID: 14508084 Review.
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
Rexer BN, Arteaga CL. Rexer BN, et al. Crit Rev Oncog. 2012;17(1):1-16. doi: 10.1615/critrevoncog.v17.i1.20. Crit Rev Oncog. 2012. PMID: 22471661 Free PMC article. Review.
80 results
Jump to page